Hostname: page-component-7dd5485656-g8tfn Total loading time: 0 Render date: 2025-10-30T12:32:11.703Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Persistent Phenothiazine-induced Oral Dyskinesia

Published online by Cambridge University Press:  29 January 2018

Peter A. Roxburgh
Peter A. Roxburgh*
Affiliation:
Department of Psychiatry, University of Alberta Hospital, Edmonton 61, Alberta, Canada
Get access Rights & Permissions [Opens in a new window]

Extract

Since the first description of persistent oral dyskinesia following phenothiazine treatment by Sigwald in 1956 a good deal of evidence has accumulated indicating the regular occurrence of this syndrome. However there is a disagreement over its incidence and the aetiological role played by phenothiazine drugs. Kline (1968) in a recent review found a total of 114 cases of ‘irreversible’ oral dyskinesia and concluded that the incidence had been misrepresented since less than two dozen of these recorded cases were previously non-brain damage.

Information

Type
Research Article
Information
The British Journal of Psychiatry , Volume 116 , Issue 532 , March 1970 , pp. 277 - 280
Copyright
Copyright © Royal College of Psychiatrists, 1970 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bandrup, E. (1961). ‘Tetrabenacine treatment in persisting dyskinesia caused by psycho-pharmacea.’ Amer. J. Psychiat., 118, 551–2.Google Scholar
Bruyn, G. W. (1962). ‘Thiopropazate dihydrochloride (Dartal) in the treatment of Huntington's chorea.’ Psychiat. Neurol. Neurochir., 65, 430–8.Google Scholar
Demars, J. C. A. (1966). ‘Neuromuscular effects of longterm phenothiazine medication, electro-convulsive therapy and leucotomy.’ J. nerv. ment. Dis., 143, 73–9.Google Scholar
Druckman, R., Seelinger, D., and Thulin, B. (1962). ‘Chronic involutionary movements induced by phenothiazines.’ J. nerv. ment. Dis., 135, 69–76.Google Scholar
Evans, J. H. (1965). ‘Persistent oral dyskinesia in treatment with phenothiazine derivatives.’ Lancet, i, 458–460.Google Scholar
Hiwter, R., Earl, C. J., and Thornicroft, S. (1964). ‘An apparently irreversible syndrome of abnormal movements following phenothiazine medication.’ Proc. Roy. Soc. Med., 57, 758–762.Google Scholar
Kune, N. W. (1968). ‘Rarity of irreversible oral dyskinesias following phenothiazines.’ Amer. J. Fsychiat., 124:8, Feb. Suppl. 48-54.Google Scholar
Lyon, R. L. (1962). ‘Drug treatment of Huntington's chorea.’ Brit. med. J., i, 1308.Google Scholar
Morphew, J. A., Barber, J. E. (1965). ‘Persistent oral dyskinesia in treatment with phenothiazine derivatives (Letter to the Editor).’ Lancet, i, 650–1.Google Scholar
Pakenham-Walsh, R. (1960). ‘Perphenazine in Huntington's chorea.’ Lancet, ii, 767.Google Scholar
Pryce, L. G., and Edwards, H. (1966). ‘Persistent oral dyskinesia in female mental hospital patients.’ Brit. J. Psychiat., 112, 983–7.CrossRefGoogle ScholarPubMed
Schmidt, W., and Jarcho, L. W. (1966). ‘Persistent dyskinesias following phenothiazine therapy.’ Arch. Neurol., 14, 369–77.Google Scholar
Sigwald, J., Bouttier, D., and Courvoisier, S. (1959). ‘Les accidents neurologiques des mädications neuroleptiques.’ Rev. Neurol., 100, 553–95.Google Scholar
Turunen, S., and Achte, K. A. (1967). ‘The bucco-linguo-masticatory syndrome as a side effect of neuroleptics therapy.’ Psychiatric Quarterly, 41, 268.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.